CANCER IMMUNOTHERAPY USING COMBINATIONS OF CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND MONOCLONAL ANTIBODIES
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jun 2, 2022
app pub date -
Feb 13, 2020
filing date -
Feb 13, 2020
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Methods of increasing or enhancing the efficacy of CAR B cell malignancy treatment regimens using immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) engineered to express chimeric antigen receptors (CAR(s)) that target malignant B cells in combination with antibodies (e.g., monoclonal antibodies, antibody-drug conjugates) that target malignant B cells are provided. Also provided are methods of treating a B cell malignancy in a subject comprising administering to the subject a CAR B cell malignancy treatment regimen and an antibody that targets malignant B cells.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully